UA77969C2 - Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound - Google Patents

Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound Download PDF

Info

Publication number
UA77969C2
UA77969C2 UA20040402736A UA20040402736A UA77969C2 UA 77969 C2 UA77969 C2 UA 77969C2 UA 20040402736 A UA20040402736 A UA 20040402736A UA 20040402736 A UA20040402736 A UA 20040402736A UA 77969 C2 UA77969 C2 UA 77969C2
Authority
UA
Ukraine
Prior art keywords
alkyl
phenyl
halogen
substituted
compound
Prior art date
Application number
UA20040402736A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA77969C2 publication Critical patent/UA77969C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
UA20040402736A 2001-11-15 2002-12-11 Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound UA77969C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103818A SE0103818D0 (sv) 2001-11-15 2001-11-15 Chemical compounds
PCT/SE2002/002055 WO2003042205A1 (en) 2001-11-15 2002-11-12 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)

Publications (1)

Publication Number Publication Date
UA77969C2 true UA77969C2 (en) 2007-02-15

Family

ID=20286005

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040402736A UA77969C2 (en) 2001-11-15 2002-12-11 Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound

Country Status (23)

Country Link
US (2) US7192973B2 (xx)
EP (1) EP1448548A1 (xx)
JP (1) JP4459622B2 (xx)
KR (1) KR20050044470A (xx)
CN (1) CN100398535C (xx)
AR (1) AR037351A1 (xx)
AU (1) AU2002353691B2 (xx)
BR (1) BR0214140A (xx)
CA (1) CA2464347A1 (xx)
HU (1) HUP0402261A3 (xx)
IL (3) IL161699A0 (xx)
IS (1) IS7256A (xx)
MX (1) MXPA04004503A (xx)
MY (1) MY137144A (xx)
NO (1) NO327221B1 (xx)
NZ (1) NZ532411A (xx)
PL (1) PL369758A1 (xx)
RU (1) RU2345990C2 (xx)
SE (1) SE0103818D0 (xx)
TW (1) TW200407139A (xx)
UA (1) UA77969C2 (xx)
WO (1) WO2003042205A1 (xx)
ZA (1) ZA200403688B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB2395059B (en) * 2002-11-05 2005-03-16 Imp College Innovations Ltd Structured silicon anode
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (sv) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
EP1654229B1 (en) * 2003-07-31 2007-05-09 AstraZeneca AB Piperidine derivatives as ccr5 receptor modulators
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
SE0303396D0 (sv) * 2003-12-16 2003-12-16 Astrazeneca Ab Chemical compounds
BRPI0509803A (pt) * 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401657D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
EP2173715A2 (en) * 2007-07-13 2010-04-14 Euroscreen S.A. Use of piperidine derivatives as agonists of chemokine receptor activity
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CA2932051A1 (en) 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Piperazine derivatives having multimodal activity against pain
TWI690512B (zh) * 2014-03-07 2020-04-11 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
EA037040B1 (ru) 2016-03-22 2021-01-29 Хелсинн Хелскеа Са Асимметричные бензолсульфонилмочевины и их применение в качестве модуляторов рецептора грелина

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) * 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
FR2096916A1 (en) 1970-07-16 1972-03-03 Synthelabo 1-(3,3-diphenylpropyl)-4-phenyl piperidine - analgesic and antiinflammatory
GB1404868A (en) 1972-12-21 1975-09-03 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
US4029801A (en) * 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
JPS5511670B1 (xx) 1971-07-13 1980-03-26
US3755584A (en) * 1972-04-03 1973-08-28 Abbott Lab Tranquilizers
FR2190430A1 (en) 1972-06-29 1974-02-01 Ferlux N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction
US3894030A (en) * 1973-01-04 1975-07-08 Janssen Pharmaceutica Nv 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US3818017A (en) * 1973-01-04 1974-06-18 Janssen Pharmaceutica Nv 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
GB1425354A (en) 1973-10-10 1976-02-18 Wyeth John & Brother Ltd Indole derivatives
FR2361880A1 (fr) 1976-04-29 1978-03-17 Science Union & Cie Nouvelles 4-amino piperidines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
GB1538543A (en) * 1976-06-23 1979-01-24 Wyeth John & Brother Ltd N-aminoalkyl piperidine derivatives
GB1532671A (en) * 1976-07-16 1978-11-15 Wyeth John & Brother Ltd Piperidine derivatives
GB1538542A (en) 1977-06-23 1979-01-24 Wyeth John & Brother Ltd Oxime derivatives
US4166119A (en) * 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4264613A (en) * 1979-08-01 1981-04-28 Science Union Et Cie, Societe Francaise De Recherche Medicale Piperidylbenzimidazolinone compounds
FR2469411A1 (fr) 1979-11-15 1981-05-22 Science Union & Cie Nouveaux derives de la piperidylbenzimidazolinone, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
EP0077427B1 (fr) 1981-10-15 1985-05-22 Synthelabo Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique
EP0095454A3 (de) 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
EP0235463A3 (en) 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
JP2515119B2 (ja) 1987-04-20 1996-07-10 日本ケミフア株式会社 ピペラジン誘導体を含有する活性酸素産生抑制ならびに活性酸素除去作用を有する医薬組成物
DE3715763A1 (de) 1987-05-12 1988-11-24 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
DE3723568C2 (de) 1987-07-16 1994-01-27 Siemens Ag Differenzstromschutzschalter
DK386089A (da) 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
FR2662162B1 (fr) 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
IE912759A1 (en) 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
AU3364493A (en) 1992-01-28 1993-09-01 Smithkline Beecham Plc Compounds as calcium channel antagonists
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
FI933472A (fi) 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH09501404A (ja) 1993-05-26 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 新規化合物
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU7947594A (en) 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
DE69522960T2 (de) 1994-12-21 2002-03-28 Neurosearch A/S, Ballerup Verfahren zur herstellung von substituierten 4-ethylpiperidinen
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5892039A (en) 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH0977742A (ja) 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
JP3064425B2 (ja) 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ カルシウムチャンネル・ブロッカーとしてのピペリジン化合物
GB9523526D0 (en) 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINE AND ITS USES.
WO1997047299A1 (en) 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
WO1998002151A2 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6015817A (en) 1996-12-05 2000-01-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001508795A (ja) 1997-01-17 2001-07-03 ブリストル−マイヤーズ・スクイブ・カンパニー Ｍｔｐインヒビター単独またはこれと他のコレステロール降下薬を組合せて用いる心臓血管疾患の発病の危険を予防または軽減する方法
AU6133098A (en) 1997-01-21 1998-08-07 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
DE19703131A1 (de) 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
HUP0004200A3 (en) 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
WO1999027928A1 (en) 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
AU2335699A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
EP1086078B1 (en) 1998-06-08 2003-02-05 Schering Corporation Neuropeptide y5 receptor antagonists
FR2780057B1 (fr) 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26659A1 (fr) * 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
JP2002527477A (ja) 1998-10-16 2002-08-27 サントリー株式会社 神経細胞保護作用物質としてのアミノフェノキシ酢酸誘導体
CA2350730A1 (en) 1998-12-18 2000-06-22 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
WO2000053600A1 (fr) 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
WO2001070689A1 (fr) 2000-03-24 2001-09-27 Meiji Seika Kaisha, Ltd. DERIVES DE LA DIPHENYLALKYLAMINE UTILES COMME AGONISTES DU RECEPTEUR DE L'OPIOIDE $g(d)
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
GB0104050D0 (en) * 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) * 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
JP4459622B2 (ja) 2010-04-28
HUP0402261A3 (en) 2009-07-28
IL196059A (en) 2010-04-29
NZ532411A (en) 2005-11-25
US20070161646A1 (en) 2007-07-12
NO20042157L (no) 2004-08-11
SE0103818D0 (sv) 2001-11-15
MXPA04004503A (es) 2004-08-11
KR20050044470A (ko) 2005-05-12
JP2005510522A (ja) 2005-04-21
IL161699A (en) 2012-12-31
IL161699A0 (en) 2004-09-27
MY137144A (en) 2008-12-31
US7192973B2 (en) 2007-03-20
WO2003042205A1 (en) 2003-05-22
RU2345990C2 (ru) 2009-02-10
PL369758A1 (en) 2005-05-02
AR037351A1 (es) 2004-11-03
AU2002353691B2 (en) 2008-04-03
CA2464347A1 (en) 2003-05-22
US20040267016A1 (en) 2004-12-30
HUP0402261A2 (hu) 2005-02-28
CN100398535C (zh) 2008-07-02
TW200407139A (en) 2004-05-16
ZA200403688B (en) 2005-08-10
IS7256A (is) 2004-05-10
RU2004111601A (ru) 2005-10-20
CN1585763A (zh) 2005-02-23
BR0214140A (pt) 2004-10-19
EP1448548A1 (en) 2004-08-25
NO327221B1 (no) 2009-05-18

Similar Documents

Publication Publication Date Title
UA77969C2 (en) Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound
US11155532B2 (en) Cyclopropylamines as LSD1 inhibitors
ES2738826T3 (es) Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de IL-12, IL-23 y/o IFNalfa
US20210032244A1 (en) Cyclopropylamines as lsd1 inhibitors
US11787779B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
JP6266639B2 (ja) ＩＬ−１２、ＩＬ−２３および／またはＩＦＮαの調節に有用なアルキルアミド置換ピリミジン化合物
AU2001244899A1 (en) New ccr5 modulators: benzimidazoles or benzotriazoles
JP2005511621A (ja) ケモカインレセプターの調節物質としての新規ピペリジン誘導体
JP2004524359A (ja) ケモカインレセプターのモジュレーターとしての新規ピペリジン誘導体
US20240262825A1 (en) Pain treating compounds and uses thereof
US20230167082A1 (en) Prodrugs in the modulation of interleukin
US11884673B2 (en) Modulators of ion channel receptors and uses thereof
US20240018129A1 (en) Compounds as pu. 1 inhibitors
TW201840531A (zh) 取代苯基二氟甲基之脯胺酸醯胺化合物
TW200300083A (en) Benzamide, heteroarylamide and reverse amides